Discovery of extracellular vesicle-delivered miR-185-5p in the plasma of patients as an indicator for advanced adenoma and colorectal cancer
Open Access
- 29 June 2023
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-14
Abstract
Background: We aimed to evaluate whether extracellular vesicles (EV)-derived microRNAs (miRNAs) can be used as biomarkers for advanced adenoma (AA) and colorectal cancer (CRC). Methods: We detected the changes in the plasma EV-delivered miRNA profiles in healthy donor (HD), AA patient, and I-II stage CRC patient groups using miRNA deep sequencing assay. We performed the TaqMan miRNA assay using 173 plasma samples (two independent cohorts) from HDs, AA patients, and CRC patients to identify the candidate miRNA(s). The accuracy of candidate miRNA(s) in diagnosing AA and CRC was determined using the area under the receiver-operating characteristic curve (AUC) values. Logistic regression analysis was performed to evaluate the association of candidate miRNA(s) as an independent factor for the diagnosis of AA and CRC. The role of candidate miRNA(s) in the malignant progression of CRC was explored using functional assays. Results: We screened and identified four prospective EV-delivered miRNAs, including miR-185-5p, which were significantly upregulated or downregulated in AA vs. HD and CRC vs. AA groups. In two independent cohorts, miR-185-5p was the best potential biomarker with the AUCs of 0.737 (Cohort I) and 0.720 (Cohort II) for AA vs. HD diagnosis, 0.887 (Cohort I) and 0.803 (Cohort II) for CRC vs. HD diagnosis, and 0.700 (Cohort I) and 0.631 (Cohort II) for CRC vs. AA diagnosis. Finally, we demonstrated that the upregulated expression of miR-185-5p promoted the malignant progression of CRC. Conclusion: EV-delivered miR-185-5p in the plasma of patients is a promising diagnostic biomarker for colorectal AA and CRC. Trial registration The study protocol was approved by the Ethics Committee of Changzheng Hospital, Naval Medical University, China (Ethics No. 2022SL005, Registration No. of China Clinical Trial Registration Center: ChiCTR220061592).Keywords
All Related Versions
Funding Information
- Shanghai Tongji Hospital Research Fund (RCQD2102)
- The National Natural Science Foundation of China (82072843)
This publication has 28 references indexed in Scilit:
- Risk of Advanced Adenoma, Colorectal Cancer, and Colorectal Cancer Mortality in People With Low-Risk Adenomas at Baseline Colonoscopy: A Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology, 2017
- Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancerScientific Reports, 2017
- Survival Following Palliative External-beam Radiotherapy of Locally Advanced and Metastatic Liver CancerAnticancer Research, 2017
- ASA-KlassifikationDer Anaesthesist, 2016
- Diagnostic Potential of Cell-Free and Exosomal MicroRNAs in the Identification of Patients with High-Risk Colorectal AdenomasPLOS ONE, 2016
- Colorectal cancer screening: a global overview of existing programmesGut, 2015
- Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal CancerCell, 2015
- Metastatic Colorectal Cancer: Current State and Future DirectionsJournal of Clinical Oncology, 2015
- World Medical Association Declaration of HelsinkiJAMA, 2013
- The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, (βHCG immunohistochemistry in advanced colorectal cancerAnnals of Oncology, 1995